- Home
- COYA vs MSLE Comparison
COYA vs MSLE Comparison
Compare COYA & MSLE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | COYA | MSLE |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | Canada |
| Employees | N/A | 21 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.8M | 147.5M |
| IPO Year | 2022 | N/A |
Fundamental Metrics
Financial Performance| Metric | COYA | MSLE |
|---|---|---|
| Price | $5.84 | $7.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $15.80 | N/A |
| AVG Volume (30 Days) | ★ 184.7K | 38.3K |
| Earning Date | 05-08-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $7,945,753.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $763.10 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 123.57 | N/A |
| 52 Week Low | $3.71 | $5.44 |
| 52 Week High | $7.75 | $13.39 |
Technical Indicators
Market Signals| Indicator | COYA | MSLE |
|---|---|---|
| Relative Strength Index (RSI) | 63.67 | 57.06 |
| Support Level | $5.40 | $6.71 |
| Resistance Level | $6.22 | $8.59 |
| Average True Range (ATR) | 0.39 | 0.41 |
| MACD | 0.08 | 0.24 |
| Stochastic Oscillator | 76.87 | 65.81 |
Price Performance
Historical ComparisonAbout COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.
About MSLE Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc is a Canadian biotechnology and drug development company. The company is developing novel therapeutics that stimulate or restore muscle regeneration in severe disorders. The company's program is focused on developing an oral therapeutic drug for Duchenne muscular dystrophy that serves to correct this dysregulation, which Satellos has identified as a root cause of the progressive nature of this disease.